Skip to content
Screener

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Eli Lilly logo
Eli LillyLLY
$590M-0.4%
Amgen logo
AmgenAMGN
2.8B0.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
500M+253,707%
Erasca, Inc. logo
Erasca, Inc.ERAS
$31K+10.7%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$182K+8.3%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.79B+460%
Enterprise value$38.5B+479%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208969
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 7)
Stockholdersʼ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 200,178,626 and 197,001,401 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1919
Additional paid-in capital4,823,4384,497,143
Accumulated other comprehensive income (loss)(622)3,237
Accumulated deficit(3,322,918)(2,869,102)
Total stockholdersʼ equity1,499,9171,631,297

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s common stock?
Revolution Medicines, Inc. (RVMD) reported common stock of $19K in Q1 2026.
How has Revolution Medicines, Inc.'s common stock changed year-over-year?
Revolution Medicines, Inc.'s common stock increased by 5.6% year-over-year, from $18K to $19K.
What is the long-term trend for Revolution Medicines, Inc.'s common stock?
Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s common stock has grown at a 22.1% compound annual growth rate (CAGR), from $7K to $19K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Revolution Medicines, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude